Full Text of SB2917 100th General Assembly
SB2917 100TH GENERAL ASSEMBLY |
| | 100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018 SB2917 Introduced 2/14/2018, by Sen. Chris Nybo SYNOPSIS AS INTRODUCED: |
| |
Amends the Epinephrine Auto-Injector Act. Provides that when an employee or agent of an authorized entity or other individual who has completed specified anaphylaxis training administers an epinephrine auto-injector in good faith, the authorized agency, and its employees and agents, including a physician, physician's assistant with prescriptive authority, or advanced practice registered nurse with prescriptive authority who provides a standing order or prescription for an epinephrine auto-injector, incur no civil or professional liability, except for willful and wanton conduct, as a result of any injury or death arising from the use of an epinephrine auto-injector. Provides that a health care professional shall not be subject to civil or professional liability for not providing an epinephrine auto-injector standing order or prescription.
|
| |
| | A BILL FOR |
|
| | | SB2917 | | LRB100 19165 MJP 34430 b |
|
| 1 | | AN ACT concerning health.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Epinephrine Auto-Injector Act is amended by | 5 | | changing Section 10 as follows: | 6 | | (410 ILCS 27/10)
| 7 | | Sec. 10. Prescription to authorized entity; use; training. | 8 | | (a) A health care practitioner may prescribe epinephrine | 9 | | auto-injectors in the name of an authorized entity for use in | 10 | | accordance with this Act, and pharmacists and health care | 11 | | practitioners may dispense epinephrine auto-injectors pursuant | 12 | | to a prescription issued in the name of an authorized entity. | 13 | | Such prescriptions shall be valid for a period of 2 years. | 14 | | (b) An authorized entity may acquire and stock a supply of | 15 | | undesignated epinephrine auto-injectors pursuant to a | 16 | | prescription issued under subsection (a) of this Section. Such | 17 | | undesignated epinephrine auto-injectors shall be stored in a | 18 | | location readily accessible in an emergency and in accordance | 19 | | with the instructions for use of the epinephrine | 20 | | auto-injectors. The Department may establish any additional | 21 | | requirements an authorized entity must follow under this Act. | 22 | | (c) An employee or agent of an authorized entity or other | 23 | | individual who has completed training under subsection (d) of |
| | | SB2917 | - 2 - | LRB100 19165 MJP 34430 b |
|
| 1 | | this Section may: | 2 | | (1) provide an epinephrine auto-injector to any | 3 | | individual on the property of the authorized entity whom | 4 | | the employee, agent, or other individual believes in good | 5 | | faith is experiencing anaphylaxis, or to the parent, | 6 | | guardian, or caregiver of such individual, for immediate | 7 | | administration, regardless of whether the individual has a | 8 | | prescription for an epinephrine auto-injector or has | 9 | | previously been diagnosed with an allergy; or | 10 | | (2) administer an epinephrine auto-injector to any | 11 | | individual on the property of the authorized entity whom | 12 | | the employee, agent, or other individual believes in good | 13 | | faith is experiencing anaphylaxis, regardless of whether | 14 | | the individual has a prescription for an epinephrine | 15 | | auto-injector or has previously been diagnosed with an | 16 | | allergy. | 17 | | (d) An employee, agent, or other individual authorized must | 18 | | complete an anaphylaxis training program before he or she is | 19 | | able to provide or administer an epinephrine auto-injector | 20 | | under this Section. Such training shall be valid for a period | 21 | | of 2 years and shall be conducted by a nationally recognized | 22 | | organization experienced in training laypersons in emergency | 23 | | health treatment. The Department shall include links to | 24 | | training providers' websites on its website. | 25 | | Training shall include, but is not limited to: | 26 | | (1) how to recognize signs and symptoms of an allergic |
| | | SB2917 | - 3 - | LRB100 19165 MJP 34430 b |
|
| 1 | | reaction, including anaphylaxis; | 2 | | (2) how to administer an epinephrine auto-injector; | 3 | | and | 4 | | (3) a test demonstrating competency of the knowledge | 5 | | required to recognize anaphylaxis and administer an | 6 | | epinephrine auto-injector. | 7 | | Training may also include, but is not limited to: | 8 | | (A) a review of high-risk areas on the authorized | 9 | | entity's property and its related facilities; | 10 | | (B) steps to take to prevent exposure to allergens; | 11 | | (C) emergency follow-up procedures; and | 12 | | (D) other criteria as determined in rules adopted | 13 | | pursuant to this Act. | 14 | | Training may be conducted either online or in person. The | 15 | | Department shall approve training programs and list permitted | 16 | | training programs on the Department's Internet website.
| 17 | | (e) When an employee or agent of an authorized entity or | 18 | | other individual who has completed training under subsection | 19 | | (d) of this Section administers an epinephrine auto-injector in | 20 | | good faith, the authorized agency, and its employees and | 21 | | agents, including a physician, physician's assistant with | 22 | | prescriptive authority, or advanced practice registered nurse | 23 | | with prescriptive authority who provides a standing order or | 24 | | prescription for an epinephrine auto-injector, incur no civil | 25 | | or professional liability, except for willful and wanton | 26 | | conduct, as a result of any injury or death arising from the |
| | | SB2917 | - 4 - | LRB100 19165 MJP 34430 b |
|
| 1 | | use of an epinephrine auto-injector. A health care professional | 2 | | shall not be subject to civil or professional liability for not | 3 | | providing an epinephrine auto-injector standing order or | 4 | | prescription. | 5 | | (Source: P.A. 99-711, eff. 1-1-17 .)
|
|